Patents by Inventor Christopher KEVIL
Christopher KEVIL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041917Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.Type: ApplicationFiled: October 13, 2023Publication date: February 8, 2024Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher Kevil, Gopi K. Kolluru
-
Patent number: 11883426Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.Type: GrantFiled: August 9, 2021Date of Patent: January 30, 2024Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher Kevil, Gopi K. Kolluru
-
Publication number: 20220409637Abstract: Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains an ACE2 externalizer, and the ACE2 externalizer is one of diminazene, diminazene aceturate, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, or prodrug thereof.Type: ApplicationFiled: September 6, 2022Publication date: December 29, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Mansoureh BARZEGAR, Ana Maria DRAGOI
-
Publication number: 20220273702Abstract: Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite.Type: ApplicationFiled: February 25, 2022Publication date: September 1, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Gopi K. Kolluru, Christopher KEVIL, Paari DOMINIC, Anthony Wayne ORR
-
Publication number: 20220169508Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.Type: ApplicationFiled: February 14, 2022Publication date: June 2, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
-
Publication number: 20220163541Abstract: The presently disclosed invention relates to a method of diagnosing Multiple Sclerosis (MS) in a patient comprising obtaining a sample from the patient, determining a level of one or more H2S generating enzymes in the sample from the patient, and diagnosing the patient with MS when the level of the one or more H2S generating enzymes is one of at least 15% higher or lower than a control level for the one or more H2S generating enzymes, and at least 10% higher or lower than a control level for the one or more H2S generating enzymes.Type: ApplicationFiled: November 26, 2021Publication date: May 26, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Elizabeth DISBROW, Karen Y. STOKES, J. Winny YUN, Pooja VEERAREDDY, Urska Cvek
-
Patent number: 11247902Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.Type: GrantFiled: June 6, 2017Date of Patent: February 15, 2022Inventors: Amol Soin, Christopher Kevil, Kyle Chan, Anthony Giordano
-
Publication number: 20220040222Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, dially disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.Type: ApplicationFiled: August 9, 2021Publication date: February 10, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher KEVIL, Gopi K. Kolluru
-
Publication number: 20210379016Abstract: Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.Type: ApplicationFiled: June 7, 2021Publication date: December 9, 2021Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Shenuarin BHUIYAN, Christopher KEVIL, Anthony Wayne ORR, Chowdhury S ABDULLAH, Richa Aishwarya
-
Publication number: 20210346409Abstract: Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutical composition containing a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains both an ACE2 externalizer and one or more ACE2 internalization preventors. Methods of treatment and pharmaceutical compositions comprising an ACE2 externalizer and one or more ACE2 internalization preventors.Type: ApplicationFiled: May 7, 2021Publication date: November 11, 2021Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Mansoureh BARZEGAR, Ana Maria DRAGOI
-
Publication number: 20210285938Abstract: A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.Type: ApplicationFiled: March 12, 2021Publication date: September 16, 2021Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher KEVIL, Elizabeth DISBROW, Johnathan Steven ALEXANDER, Karen Y. STOKES
-
Patent number: 10864229Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.Type: GrantFiled: April 10, 2017Date of Patent: December 15, 2020Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Christopher Kevil, David Lefer, Rakesh Patel
-
Publication number: 20200297756Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.Type: ApplicationFiled: June 11, 2020Publication date: September 24, 2020Inventors: Christopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES
-
Publication number: 20200297659Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated conditions comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via diallyl disulfide (DADS), and the NO mediated condition includes one of inflammation, wound healing, and an infection.Type: ApplicationFiled: June 9, 2020Publication date: September 24, 2020Inventors: Christopher KEVIL, Sibile PARDUE
-
Patent number: 10697960Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.Type: GrantFiled: November 24, 2015Date of Patent: June 30, 2020Assignee: BOARD OF SUPERVISORS OR LOUISANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventors: Christopher Kevil, Robert McVie, John Glawe
-
Patent number: 10675253Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample.Type: GrantFiled: March 26, 2018Date of Patent: June 9, 2020Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Christopher Kevil, Sibile Pardue
-
Publication number: 20200138966Abstract: The present invention is related to methods and pharmaceutical compositions comprising a Slit-2 and SDF-1? bifuncitional peptide conjugate having a Slit-2 ligand binding domain and an SDF-1? ligand binding domain.Type: ApplicationFiled: January 29, 2018Publication date: May 7, 2020Inventors: Christopher KEVIL, John CHIDLOW, Kevin PAVLICK
-
Publication number: 20200121714Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.Type: ApplicationFiled: June 6, 2017Publication date: April 23, 2020Inventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
-
Patent number: 10596188Abstract: A method of treating neuropathy in a subject, the method comprising identifying a subject who has neuropathy; and administering to the subject a pharmaceutical composition comprising one of inorganic nitrite and a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 23, 2017Date of Patent: March 24, 2020Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Christopher Kevil
-
Publication number: 20200085861Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.Type: ApplicationFiled: October 11, 2019Publication date: March 19, 2020Inventors: Christopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES